tctMD: SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

November 9, 2021

Through 5 years, TAVI with a self-expanding valve provided clinical outcomes similar to those seen with surgery in an intermediate-risk population, according to continued follow-up of the SURTAVI trial.

Dr. Ketih Allen, surgeon at Saint Luke's Mid America Heart Institute, commented on the results of the SURTAVI Trial during a panel discussion that through 5 years, SURTAVI “continues to show that if you’re not going to get a mechanical valve, TAVR is . . . a really great option, and I think it should be first in the armamentarium.”

Read the full article and more about the SURTAVI Trail in tctMD: SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years.


Related Content

TAVR: Sisters get Innovative Treatment at Saint Luke’s
Saint Luke’s dedication to research means more patients have alternatives to care—like Hilda Lankard and Agnes Lickteig.
Healio: No difference in sustained health status improvements in TAVR vs. surgical AVR
Patients who had TAVR had similar health status after five years with those who had surgical AVR, according to a new study by Dr. Suzanne Arnold.
Studies find transcarotid TAVR safest alternate, while minimizing hospital stays in the COVID-19 era
Transcarotid access was found to be the safest alternate option for transcatheter aortic valve replacement (TAVR), according to two recent large studies. Dr. Keith Allen explains.